A natural protein based platform for the delivery of Temozolomide acid to glioma cells

Proposed hypothesis in this study. Brain tumours overexpress SPARC protein which is responsible for the uptake of albumin nanoparticles (HSA NPs). Temozolomide (TMZ), a DNA alkylating agent, is the first line drug for treatment of glioma. Thus the delivery of Temozolomide acid (TMZA), a derivative of TMZ into HSA NPs (TMZA-HSA NPs) is hypothesized to ensure delivery of TMZA into glioma cells, overcoming the BBB and ensuring TMZ delivery in sufficient amounts for improved glioma therapy.